PTIX (protagenic.com) יחס שווי שוק לשווי בספרים

Protagenic Therapeutics (PTIX) develops patent-protected biologics to combat depression, seeking to attract strategic partners through the development of therapeutic peptides. The company's relative capitalization metric on GURU.Markets reflects current asset valuation trends, where -0.30 indicates the current level. The business model assumes high R&D expenditures followed by a transition to high-margin mass production of pharmaceuticals.

This ratio reflects the premium or discount of a business's market value relative to its net assets. By analyzing the market cap to book value ratio, an investor assesses the degree of capital overvaluation. The metric compares market expectations with actual book value. For Protagenic Therapeutics (PTIX), a high variance is driven by the R&D stage. The potential of neuropeptide drugs for depression therapy is priced into a future value that exceeds current balance sheet figures.